HBIO— HARVARD BIOSCIENCE INC

Health CareLife Sciences Tools & Services$29M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	$86.5M-8.1%	$94.1M-16.1%	$112.3M-1.0%	$113.3M
Cost of revenues	$36.6M-6.9%	$39.4M-14.7%	$46.2M-12.1%	$52.5M
Gross profit	$49.9M-8.9%	$54.8M-17.1%	$66.1M+8.6%	$60.8M
Sales and marketing expenses	$19.2M-13.5%	$22.2M-7.7%	$24.1M-3.9%	$25.0M
General and administrative expenses	$17.7M-17.5%	$21.5M-5.6%	$22.8M-7.1%	$24.5M
Research and development expenses	$8.8M-15.2%	$10.4M-11.5%	$11.8M-4.6%	$12.3M
Amortization of acquired intangible assets	$4.0M-23.4%	$5.3M-4.9%	$5.5M-9.8%	$6.1M
Goodwill impairment - Note 5	$48.0M	$0	—	—
Other operating expenses - Note 2	$729K-54.7%	$1.6M+2169.0%	$71K	—
Total operating expenses	$98.5M+61.5%	$61.0M-5.0%	$64.2M-5.3%	$67.8M
Operating loss	-$48.6M-682.2%	-$6.2M-427.9%	$1.9M+127.3%	-$6.9M
Interest expense	-$4.9M-39.1%	-$3.5M+1.5%	-$3.6M-40.9%	-$2.5M
Loss on pension settlement - Note 8	-$1.2M	$0	—	—
Loss on equity securities - Note 12	$0+100.0%	-$1.6M-152.1%	-$632K	—
Other expense, net	-$2.7M-717.2%	-$325K-43.2%	-$227K-175.2%	$302K
Total other expense	-$8.8M-61.5%	-$5.5M-22.6%	-$4.5M-98.1%	-$2.2M
Loss before income taxes	-$57.4M-392.0%	-$11.7M-356.4%	-$2.6M+72.2%	-$9.2M
Income tax (benefit) expense	-$686K-192.7%	$740K-13.9%	$859K+154.9%	$337K
Net loss	-$56.7M-357.1%	-$12.4M-263.3%	-$3.4M+64.1%	-$9.5M
Basic and diluted loss per share (in dollars per share)	-$1280.00-357.1%	-$280.00-250.0%	-$80.00-34682.6%	-$0.23
Basic and diluted (in shares)	44.4M+2.0%	43.5M+2.6%	42.4M+2.4%	41.4M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.